In this study, we sought to investigate the prognostic value of T‐cell marker mRNA expression (CD3, CD8, and FOXP3), as well as their association with TILs and RANK, RANKL, and OPG mRNA expression, in a large cohort of early‐stage breast cancer patients treated with anthracycline‐based adjuvant chemotherapy in the context of two prospective phase III randomized trials. Here, CD8A is linked to breast cancer.